Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Waters Introduces the ACQUITY QDa Detector

Published: Monday, October 07, 2013
Last Updated: Monday, October 07, 2013
Bookmark and Share
The Waters® ACQUITY QDa™ Detector is the first mass detector to bring high-quality, mass spectral data to chromatographic separations.

Designed as a synergistic component of a chromatographic system, the ACQUITY QDa Detector is compatible with Waters ACQUITY® UltraPerformance LC® (UPLC®), ACQUITY UltraPerformance Convergence Chromatography™ (UPC2®), Alliance® high performance liquid chromatography (HPLC) and Waters supercritical fluid chromatography (SFC) and LC-based purification systems. 

“The ACQUITY QDa Detector is the realization of a vision that started 20 years ago at Waters,” said Art Caputo, President, Waters Division. "We foresaw a day when we could blend chromatography and mass spectrometry technologies together in a way that gives every analytical scientist access to mass spectral data regardless of their previous experience with mass spectrometry. The ACQUITY QDa Detector adds a whole new dimension to separation science and it is the most progressive leap forward in chromatography detection since the first photodiode detectors were introduced decades ago." 

The result of 30 years of Waters mass spectrometry experience and innovation and featuring 37 new patents and patents pending, the ACQUITY QDa Detector addresses the barriers of complexity, size and cost that have hindered the adoption of mass spectrometry for everyday use. It is purposefully designed for analytical scientists who need mass spectral data without the complexity of a mass spectrometer. With the on/off simplicity that analytical scientists have long wanted from mass spectrometry, the ACQUITY QDa Detector fully automates sample analysis and eliminates sample-specific adjustments for certainty in sample results, from user to user and system to system. Robust and reliable enough for routine use, the ACQUITY QDa Detector generates the high quality mass spectral data expected of a single quadrupole mass spectrometer in a mass detector no bigger than a familiar photodiode array (PDA) detector.  

The ACQUITY QDa Detector complements optical detection, such as the PDA detector, by confirming the identity of compounds with mass spectral information. Additionally, the ACQUITY QDa Detector extends the limits of sample detection for a chromatographic separation by quantifying compounds having no UV response or that are present at levels not detectable and quantifiable by optical detection.  By simplifying laboratory workflows, the detector enhances the value of every analysis and increases productivity by eliminating the need to run additional assays or turn to time-consuming alternative techniques in order to establish with certainty the levels and identity of specific sample compounds. 

The ACQUITY QDa Detector is available now for separations systems running Empower® 2 & 3 Chromatography Data System (CDS) software, including enterprise deployment with automated qualification. Empower 3 makes mass and UV spectral data processing as integrated as the separations systems they were acquired on. The ACQUITY QDa Detector is also available now for MassLynx® 4.1 Mass Spectrometry Software.

The ACQUITY QDa Detector is set to transform pharmaceutical discovery & development, chemical materials and food laboratories engaged in method development, sample profiling, synthetic chemistry and purification.

Waters is now shipping the new mass detector worldwide.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Waters, Chinese Pharmacopeia Commission Establish Joint Open Laboratory
Located in the laboratory building of Beijing Zhendong Guangming Drug Research Institute, the new facility is over 400m2.
Thursday, July 10, 2014
Waters, Ireland’s NIBRT Partner on Training and Research to Advance Burgeoning Biopharma Industry
Will increase large molecule characterization capacity and knowledge, help deliver new, more effective therapeutic options.
Tuesday, April 03, 2012
Waters and ACS Partner on New Sci-Mind Separation Science Training Program
From ACS Department of Professional Education, Sci-Mind learning community is designed to challenge chemists.
Friday, March 23, 2012
Waters Corporation Welcomes King’s College London into Waters Centers of Innovation Program
Aim is to support the drug control centre’s efforts to develop novel analytical methods for sports drug testing and toxicological studies.
Thursday, November 11, 2010
Waters and DAISO Sign Marketing Agreement for Bulk Process Chromatography Media
Waters to make DAISO media available to pharmaceutical and biopharmaceutical purification customers.
Thursday, February 18, 2010
Waters Acquires Thar Instruments
The acquisition establishes “Green” separation science leadership and expands chromatography application range.
Friday, February 06, 2009
Small Molecule Science Takes Center Stage at CoSMoS 2006
Researchers, journalists and academics will meet for the 3rd annual Conference on Small Molecule Science to be held from July 24-27 at the Omni Hotel, San Diego.
Tuesday, July 18, 2006
Waters Achieves top Honors Again for World-Class Customer Service
Waters Corporation receives its fifth consecutive Omega Northface Scoreboard SM Award.
Thursday, May 25, 2006
Scientific News
Combining Chemotherapy With Immune-Blocking Drug Could Stop Cancer Growing Back
Giving patients a drug that blocks part of the immune system from going into overdrive might help prevent cancer coming back in some people.
Researchers Pioneer Use of Capsules to Save Materials
Wax capsule delivery systems can simplify a wide range of chemistry transformations.
Photoredox Catalyst Unlocks New Pathways for Nickel Chemistry
Using a light-activated catalyst, researchers have unlocked a new pathway in nickel chemistry to construct carbon-oxygen (C-O) bonds that would be highly valuable to pharmaceutical and agrochemical industries.
Scientists Determine How Antibiotic Gains Cancer-Killing Sulfur Atoms
In a discovery with implications for future drug design scientists have shown an unprecedented mechanism for how a natural antibiotic with antitumor properties incorporates sulfur into its molecular structure, an essential ingredient of its antitumor activity.
Familiar Drugs May Block Ebola Virus Infection
A well-known class of molecules, many of which are already in use therapeutically, may be able to block the Ebola virus’s entry into cells and halt the disease in its tracks, according to researchers at the University of Illinois at Chicago.
New Extra ‘Sticky’ Microgel Could Revolutionise Bladder Cancer Treatment
Researchers have designed a new super-efficient way of delivering an anti-cancer drug which could extend and improve the quality of life for bladder cancer patients - and perhaps save lives.
Common Class of ‘Channel Blocking’ Drugs May Find a Role in Cancer Therapy
Discoveries in fruit flies prompt unusual treatment of patient with metastatic disease.
Common Medications Could Delay Brain Injury Recovery
Drugs used to treat common complaints could delay the recovery of brain injury patients according to research by University of East Anglia (UEA) and University of Aberdeen scientists, published today in Brain Injury.
Scientists Make Strides in Therapy Preventing Addiction Relapse
Single Injection of Drug Candidate Prevents Meth Relapse in Animal Models.
New Clot-Busting Treatments Target Number One Killer
Australian researchers funded by the National Heart Foundation are a step closer to a safer and more effective way to treat heart attack and stroke via nanotechnology.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!